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Abstract
HIV-1 variants resistant to small molecule CCR5 inhibitors recognize the inhibitor-CCR5 complex, while also interacting with
free CCR5. The most common genetic route to resistance involves sequence changes in the gp120 V3 region, a pathway
followed when the primary isolate CC1/85 was cultured with the AD101 inhibitor in vitro, creating the CC101.19 resistant
variant. However, the D1/86.16 escape mutant contains no V3 changes but has three substitutions in the gp41 fusion
peptide. By using CCR5 point-mutants and gp120-targeting agents, we have investigated how infectious clonal viruses
derived from the parental and both resistant isolates interact with CCR5. We conclude that the V3 sequence changes in
CC101.19 cl.7 create a virus with an increased dependency on interactions with the CCR5 N-terminus. Elements of the CCR5
binding site associated with the V3 region and the CD4-induced (CD4i) epitope cluster in the gp120 bridging sheet are more
exposed on the native Env complex of CC101.19 cl.7, which is sensitive to neutralization via these epitopes. However, D1/
86.16 cl.23 does not have an increased dependency on the CCR5 N-terminus, and its CCR5 binding site has not become
more exposed. How this virus interacts with the inhibitor-CCR5 complex remains to be understood.
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Introduction
Small molecule drugs or drug candidates bind to the cell surface
CCR5 protein and prevent human immunodeficiency virus type 1
(HIV-1) from using it as a coreceptor for entry into CD4-positive
target cells [1,2]. These compounds, which include the licensed
drug maraviroc (MVC) and the clinical candidate vicriviroc (VVC,
also known as SCH-D), bind within the transmembrane helices of
CCR5 and stabilize the protein in a conformation that cannot be
recognized efficiently by the HIV-1 gp120 surface glycoprotein
[3–7]. The interaction between gp120 and CCR5 is considered to
involve two structural elements. The CCR5 N-terminus (NT)
interacts with a site on gp120 that involves the 4-stranded bridging
sheet region and the base of V3, which assembles upon CD4
binding, while the second extracellular loop (ECL-2) of CCR5
interacts with a second region of V3 located near its tip [8–12].
Viruses resistant to the small molecule CCR5 inhibitors can be
generated in vitro and in vivo [13–17]. The dominant route to resistance
involves the acquisition of sequence changes that render gp120 capable
of recognizing the inhibitor-CCR5 complex, without losing its ability to
also interact with the free coreceptor [16,18]. Hence the escape
mutants become inhibitor-tolerant, but not inhibitor-dependent. The
most common genetic route to resistance is the acquisition of multiple
sequence changes in V3 [13,16,19–21]. This pathway was followed
when the primary R5 isolate CC1/85 was cultured with the AD101
inhibitor in vitro, creating the CC101.19 resistant variant. However, we
have described a V3-independent route to the same phenotype that
was taken by the same input virus under the selection pressure of a
similar compound, VVC, to yield the D1/86.16 escape mutant
[14,22]. We have recently shown that this alternative pathway involves
three sequence changes in the fusion peptide (FP) region of the gp41
transmembrane glycoprotein. These changes exert broadly similar
effects to the more conventional V3 changes, in that the resistant virus
was able to use the inhibitor-CCR5 complex for entry [22].
By using CCR5 point-mutants and gp120-targeting agents, we now
seek to learn more about how the parental and both resistant viruses
interact with the coreceptor.A small molecule that interacts with gp120
at the V3 region, IC9564, had differential activities against the various
viruses, as did monoclonal antibodies (MAbs) and polyclonal Abs
directed against the V3 region and MAbs to the CD4-induced epitopes
associated with CCR5 binding. We conclude that the V3 sequence
changes in CC101.19 create a variant that is more dependent than its
parent on interactions with the CCR5 NT. Elements of the CCR5
binding site associated with the V3 region and the CD4i epitope cluster
in the bridging sheet have become more exposed on the native Env
complex of this virus, and hence accessible to neutralizing antibodies
(NAbs). However, the D1/86.16 variant with changes in the gp41 FP
has followed a different pathway to resistance that does not involve an
increased dependency on the CCR5 NT, and in which the CCR5
b i n d i n gs i t eh a sn o tb e c o m em o r ee xposed. How this virus interacts
with the inhibitor-CCR5 complex therefore remains to be determined.
Results
Differential usage of CCR5 mutants by parental and
escape mutant viruses
Isolates CC101.19 and D1/85.16 are resistant variants derived
from the primary R5 isolate CC1/85 after selection with the small
PLoS Pathogens | www.plospathogens.org 1 August 2009 | Volume 5 | Issue 8 | e1000548molecule CCR5 inhibitors AD101 and VVC, respectively [14,20].
As the emphasis of the present study was to gain a better
understanding of how resistant variants interact with CCR5, we
used infectious, Env-chimeric clonal viruses CC101.19 cl.7 and
D1/85.16 cl.23, derived from the above resistant isolates, and
compared their properties with inhibitor-sensitive clones of the
parental isolate, CC1/85. A multiple sequence alignment based on
the Env amino-acid sequences of seven parental clones derived
from the CC1/85 isolate shows that CC1/85 cl.7 and CC1/85
cl.6 were the most similar to CC101.19 cl.7 and D1/85.16 cl.23,
respectively (data not shown). For simplicity, we have summarized
these results in a tree based on the percent similarity between the
four clones (Fig. 1A,B). The majority of the amino-acid differences
between the two pairs of viral clones are in the V4 and V5 regions
of gp120. Taking into account also the replication properties of the
various parental clones, we chose to use CC1/85 cl.7 for
comparisons with CC101.19 cl.7, and CC1/85 cl.6 as a
comparator for D1/85.16 cl.23. Clones CC101.19 cl.7 and D1/
85.16 cl.23 contain amino acid changes that have been shown to
be necessary and sufficient to confer resistance to small molecule
CCR5 inhibitors [20,22]. Thus, CC101.19 cl.7 has four
substitutions in the V3 region of gp120 (K305R, H308P, A316V
and G321E), while D1/85.16 cl.23 contains three changes in the
gp41 FP (G516V, M518V and F519I) (Fig. 1C). The phenotypic
properties of these four clones that were derived from the studies
outlined below are summarized in Table S1.
The four clones used in this study recapitulate the phenotypes of
the corresponding isolates in respect of VVC sensitivity. Thus, in
an assay using PBMCs, the parental isolate, CC1/85, was
completely inhibited by VVC concentrations $100 nM, whereas
replication of the two resistant isolates was not affected by the
presence of VVC (Fig. 2A). Similarly, the parental clones CC1/85
cl.7 and CC1/86 cl.6 were each completely inhibited by VVC
concentrations $10 nM (10-fold lower then that needed for
complete inhibition of the isolate). In contrast, replication of the
resistant clones in PBMCs was either modestly enhanced (for
CC101.19 cl.7) or unaffected (for D1/85.16 cl.23) by VVC
(Fig. 2B). Env-pseudotyped viruses derived from the above clones
behaved similarly to the infectious, chimeric clonal viruses in U87-
CD4-CCR5 assays (data not shown). Similar data were obtained
using other small molecule CCR5 inhibitors such as AD101,
maraviroc and aplaviroc (data not shown).
To determine whether the resistant clones differ from each
other, and from the corresponding parental clone, in how they
interact with CCR5, we first used a panel of point-mutated
coreceptors (Fig. 3, Table 1). The composition of the test panel was
biased towards mutants of the NT and ECL2, since these CCR5
domains have the greatest influence on HIV-1 entry [10,23–25].
The various CCR5 mutants were transiently expressed in U87-
CD4 cells for 48 h before incubation for an additional 72 h with
luciferase-expressing, Env-pseudotyped clonal viruses derived from
the parental and resistant isolates. The CCR5 mutants were all
expressed at comparable levels on the cell surface as determined by
FACS (data not shown). The relative level of entry via each mutant,
compared to wild-type CCR5, was calculated for each test virus, to
identify coreceptor variants that were used with different efficiency
under the conditions of this single-cycle assay (Table 1). As
expected, none of the Env-pseudotyped viruses could use the D18
mutant that lacked the first 18 residues of the CCR5 NT [26,27].
The tyrosine residues at NT positions 10 and 14 are sulfated, a
modification known to be important for HIV-1 entry [28,29].
Accordingly, none of the viruses utilised the Y10A/Y14A double
mutant efficiently, although D1/85.16 cl.23 was able to use it for
low-level entry (Table 1). Three other mutations adversely affected
entry of all four viruses to a meaningful extent (,50% entry
compared to wild-type): D11A in the NT, C178A and F189A in
ECL2 (Table 1). This outcome is consistent with previous studies on
thesamemutants with differenttest viruses, and arisesbecause these
residues (particularly D11 and C178) are important for maintaining
the appropriate CCR5 conformation [25,30]. The entry of various
viruses via certain other mutants was reduced to a lesser extent (25–
50%). Such reductions may be biologically relevant but can be
difficult to distinguish from background variation with confidence.
Several mutations differentially affected entry of the four Env-
pseudotyped viruses. Thus, CC101.19 cl.7 was particularly affected
by NT mutations Y10A, Y14A, Y14F, Y14Q and C20A (Table 1);
depending on the mutation, the entry of this virus was reduced to
#26% of the extent conferred by wild-type CCR5. The identity of
the substituted residue at position 14 was an additional variable;
more specifically, CC101.19 cl.7 could use the Y14Q mutant with
low efficiency (,20%), but not Y14A or Y14F (,1% entry). In
contrast, D1/85.16 cl.23 could enter via all three of the residue-14
mutants at .70%of thelevel mediated bywild-type CCR5;indeed,
this escape mutant and its parent, CC1/85 cl.6, were little affected
by the identity of the residue at position 14 (Table 1). These
observations, taken together, suggest that the tyrosine residues at
positions 10 and 14 were both required for efficient entry of
CC101.19 cl.7, whereas the presence of either sulfated-tyrosine was
sufficient to mediate entry of the other three viruses to at least some
extent. Conversely, the ECL2 mutations F182A and P183A
impaired entry of both resistant viruses a little more than they did
the two parental clones, while the Y187A and F193A changes
selectively, although modestly, affected entry of D1/85.16 cl.23
(Table 1). The triple Ala mutants with changes at residues 184–186
and 187–189 were, however, used by all four viruses (Table 1).
Overall, the pattern of entry via the various CCR5 mutants
suggests that the two resistant viruses differ markedly in how they
interact with the coreceptor. Thus, CC101.19 cl.7 is particularly
reliant on the sulfated tyrosine residues at positions 10 and 14 in the
NT, but this is not the case for D1/85.16 cl.23. The latter virus is
somewhat more affected by some substitutions within ECL2, but
notdramaticallyso.TheirdifferentialsensitivitytoCCR5mutations
Author Summary
Human immunodeficiency virus type 1 (HIV-1) is the
causative agent of AIDS. HIV-1 entry into target cells is
triggered by the interaction of the viral envelope
glycoproteins with a cell-surface receptor (CD4) and a co-
receptor (CCR5), and culminates in fusion of the viral and
cell membranes. Small molecule inhibitors that bind to
CCR5 are a new class of drug for treating HIV-1-infected
people. However, HIV-1 can evolve ways to become
resistant to these compounds, by acquiring mutations
that alter how its envelope glycoproteins (gp120-gp41)
interact with CCR5. In this study, we investigated how two
resistant viruses gained the ability to use the inhibitor-
bound form of CCR5 through two different mechanisms. In
the first virus, four amino acid substitutions in the V3
region of gp120 created an increased dependency on
interactions with the CCR5 N-terminus. These changes
altered the configuration of gp120, increasing the
exposure of antibody epitopes in the V3 region and the
CD4i epitope cluster associated with the CCR5 binding site.
In contrast, the second virus, which became resistant via
three sequence changes in the gp41 subunit, did not
become more dependent on the CCR5 N-terminus and
remained resistant to neutralization by antibodies against
elements of the CCR5 binding site.
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the coreceptor. A corollary of the increased dependence of
CC101.19 cl.7 on the CCR5 NT might be that the region near
the tip of V3 is now less involved in gp120-CCR5 binding,
compared to both of the parental clones and D1/85.16 cl.23. If so,
the 4 amino acid changes in the V3 region of CC101.19 cl.7 might
be acting to change the orientation of V3 with respect to the rest of
gp120, disrupting its ability to interact with ECL2 while increasing
the accessibility of the bridging sheet to the NT. This argument
would not apply to D1/85.16 cl.23, which has followed a different
route to resistance that is less apparent from the studies using the
CCR5 mutants. To gain information on what changes in Env
conformation took place as resistance developed, we measured the
responses of the two resistant viruses to compounds that interact
with different regions of gp120.
Sensitivity to inhibitors of gp120-CD4 binding does not
correlate with VVC resistance
We first used various inhibitors of the gp120-CD4 interaction to
assess whether there are differences in the CD4-binding events of
the VVC-sensitive and -resistant clones that could influence the
subsequent conformational changes in gp120 involved in creation
of the CCR5 binding site. When the four clones were incubated
with a range of sCD4 concentrations before infection of PBMCs,
CC1/85 cl.7 and CC101.19 cl.7 were both highly sensitive, with
IC50 values ,0.1 mg/ml (Fig. 4A, Table 2). In contrast, D1/85.16
cl.23 was ,100-fold less sensitive to sCD4 and CC1/85 cl.6 was
almost completely resistant (Fig. 4A, Table 2). Of note is that
CC1/85 cl.7 and CC101.19 cl.7 are unusually sensitive to sCD4,
compared to the corresponding isolates (IC50 values ,5 mg/ml)
and to typical primary isolates, which typically have IC50 values
.10 mg/ml [31–34]. The same data pattern was observed with
CD4-IgG2 (PRO542); again CC1/85 cl.7 and CC101.19 cl.7
were much more sensitive than D1/85.16 cl.23 and all three of the
isolates (Table 2). Hence the sCD4 and CCR5 inhibitor sensitivity
profiles of these four clones are not correlated; one parental and
one VVC-resistant clone are sCD4-sensitive, the other two are
sCD4-resistant. In contrast to what was observed using sCD4 and
CD4-IgG2, the four clones (and the corresponding isolates) did not
differ markedly in their sensitivities to MAb b12 against the CD4-
binding site on gp120 or to the anti-CD4 MAb RPA-T4 that
inhibits gp120-CD4 binding (Fig. 4B,C and data not shown).
Figure 1. Sequence analysis of parental and resistant viruses. (A) Tree view of a multiple Env amino acid sequence alignment of the CC1/85-
derived clones (cl.6, cl.7) and the two CCR5 inhibitor-resistant clones, CC101.19 cl.7 and D1/85.16 cl.23. (B) Alignment of gp120 sequences from
residues 370–470, consisting of a segment of C3, V4, C4 and V5. The consensus amino acid sequence is given on the bottom line. Dots represent
identical residues for all four clones, with gaps indicated by asterisks. Residues that are different between the two pairs (D1/85.16 cl.23 and CC1/85
cl.6 on the one hand, CC101.19 cl.7 and CC1/85 cl.7 on the other) are boxed. (C) Schematic representation of HIV-1 Env clones. The V3 and FP
sequences of representative clones of CC1/85, CC101.19 and D1/85.16 are depicted. CC101.19 cl.7 contains four substitutions in the V3 region of
gp120 (K305R, H308P, A316V and G321E), while D1/85.16 cl.23 contains three substitutions in the gp41 FP (G516V, M518V and F519I) [20,22]. These
sequence differences are highlighted in bold and underlined; they are necessary and sufficient to confer resistance, although there are other changes
elsewhere in Env. Amino acid numbering is based on HxB2 Env.
doi:10.1371/journal.ppat.1000548.g001
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usually not predictive of how the same agents interact with the
native Env trimer and neutralize the corresponding virus [35–37].
However, because of the unusual characteristics of the CCR5
inhibitor resistant viruses, we considered it worth assessing
whether the differential inhibition patterns described above might
be manifested at the level of the gp120 monomer. In a gp120-
capture ELISA, CD4-IgG2 bound with equivalent affinity to
gp120 proteins derived from all four parental clones and resistant
clones (Fig. 5A). Hence the differential sensitivity of the
corresponding viruses to CD4-based inhibitors (Table 2) is not
manifested at the level of the gp120 monomer, consistent with
previous findings [35–37].
The small molecule HIV-1 gp120 ligand, BMS-806, was initially
classified as an inhibitor of gp120-CD4 binding [38]. However, it
also inhibits subsequent conformational changes in the gp120-gp41
complex [39]. It is not a direct competitor with gp120 for CD4
binding but instead reduces the affinity of CD4 for gp120
allosterically, without inducing the CD4i epitope [40]. The BMS-
806 infectivity-inhibition pattern for the four clones was the converse
of that seen with sCD4 (Fig. 4D, Table2). Thus,D1/85.16 cl.23 and
CC1/85 cl.6 were markedly more sensitive to BMS-806 than the
other two clones (IC50 values ,20-fold lower). D1/85.16 was also
the most sensitive of the three isolates to BMS-806, by ,7 to 10-fold
(Table 2). We then tested whether the differential sensitivities of the
viral clones to BMS-806 were also reflected at the gp120 monomer
level. In an ELISA, BMS-806 inhibited the binding of CD4-IgG2 to
gp120s from D1/85.16 cl.23 and CC1/85 cl.6 more efficiently than
to gp120s fromCC1/85 cl.7and CC101.19 cl.7(Fig. 5B). Hence the
increased BMS-806 sensitivity of clones D1/85.16 cl.23 and CC1/
85 cl.6 probably arises at the gp120 monomer level.
Given the similarities at the amino acid sequence level between
CC1/85 cl.7 and CC101.19 cl.7 (Fig. 1A,B), it appears likely that
CC101.19 cl.7 evolved from a sCD4-sensitive, minor variant
present in the uncloned isolate that is related to CC1/85 cl.7.
Conversely, D1/85.16 cl.23 presumably evolved from one of the
more prevalent sCD4-resistant viruses in the CC1/85 isolate.
These assumed relationships should be noted when interpreting
later experiments.
Increased sensitivity of CC101.19 cl.7, but not D1/85.16
cl.23, to CD4i MAbs
MAbs in the CD4i family bind to a CD4-induced epitope on
gp120 that substantially overlaps the element of the CCR5 binding
site that is located within the bridging sheet and the base of V3.
Their interaction with gp120 mimics that of the critical sulfated
tyrosine residues in the CCR5 NT [10,41]. CC101.19 cl.7 was
markedly more sensitive than CC1/85 cl.7, CC1/85 cl.6 and D1/
85.16 cl.23 to neutralization by CD4i MAbs 48d and 17b
(Fig. 6A,B), and also by MAbs ED10, 2.1C and 3.1H against the
same epitope cluster (data not shown). Among those five CD4i
MAbs, only 48d had even limited neutralizing activity against the
two parental clones, and none of them had any detectable activity
against D1/85.16 cl.23 (Fig. 6, and data not shown). None of the
CD4i MAbs had detectable neutralizing activity against any of the
uncloned parental or VVC-resistant isolates (IC50 values
.100 mg/ml) (data not shown).
In a gp120-capture ELISA, D1/85.16 cl.23 and CC1/85 cl.6
gp120s were the most reactive with MAb 17b (Fig. 5C), which is in
marked contrast to the infection-inhibition experiments where
D1/85.16 cl.23 and CC1/85 cl.6 were the clones least sensitive to
17b and the related 48d MAb (Fig. 6A,B). Hence although the 17b
epitope is well exposed on the gp120 monomer from these VVC-
resistant viruses, that exposure is not relevant to what happens
with the infectious virus. In the presence of sCD4, 17b bound
almost equally well to all four gp120 monomers (Fig. 5C). sCD4
therefore has only a small inductive effect on the 17b epitope on
the D1/85.16 cl.23 and CC1/85 cl.6 gp120s, but a much more
marked action on gp120s from CC1/85 cl.7 and CC101.19 cl.7
(Fig. 5C). BMS-806 partially inhibited 17b binding to all four
gp120s, but its blocking activity was less efficient with CC101.19
cl.7 gp120 than with the other three (Fig. 5D).
The significantly greater sensitivity to CD4i MAbs of CC101.19
cl.7 compared to CC1/85 cl.7 stands in marked contrast to the
similar sCD4 sensitivities of these two clones (compare Fig. 4A and
Fig. 6). The increased sensitivity of CC101.19 cl.7 to CD4i MAbs
may, therefore, be informative about how this clone is VVC-
resistant. The simplest explanation is that at least one major
element of its CCR5 binding site has become accessible or has
been formed constitutively on the native Env complex, and not
just after CD4 has bound.
Differential inhibition of the VVC-resistant viruses by a
small molecule V3 ligand
IC9564 is a small molecule that binds to positively charged
residues on the N-terminal side of the V3 stem and/or tip [42,43].
It does not inhibit CD4 binding or CD4-induced conformational
Figure 2. VVC sensitivity of parental and resistant isolates and
clones. (A) The parental isolate CC1/85 (squares) and the resistant
isolates CC101.19 (triangles) and D1/85.16 (circles) were tested for VVC
sensitivity in an assay of HIV-1 replication in PBMCs. (B) Clones derived
from the parental isolate, CC1/85 cl.7 (squares) and CC1/85 cl.6
(diamonds), or from the resistant isolates, CC101.19 cl.7 (triangles)
and D1/85.16 cl.23 (circles), were used to infect PBMCs in the presence
of VVC. The data in both panels A and B represent the extent of
inhibition of replication (p24 antigen production) relative to that in the
absence of VVC (100% replication, 0% inhibition). The data points in
panels A and B are derived from a single, representative experiment.
doi:10.1371/journal.ppat.1000548.g002
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necessary for fusion, perhaps by locking gp120 in a CD4-induced
conformation [43,44]. CC101.19 cl.7 was the most sensitive of the
four clones to IC9564, with an IC50 value 11-fold lower than
CC1/85 cl.7 (0.62 nM compared to 7.2 nM, respectively). D1/
85.16 cl.23 and CC1/85 cl.6 were both much less sensitive to
IC9564, with IC50 values of 690 and 150 nM, respectively (Fig. 7,
Table 2). The relative resistance (,1100-fold) of D1/85.16 cl.23
compared to CC101.19 cl.7 was only partially recapitulated by the
corresponding isolates, for which there was a 10-fold differential in
IC50 values (Table 2).
These observations suggest that the V3 binding site for IC9564
is significantly more accessible on CC101.19 cl.7, or the
corresponding interaction with CCR5 more easily disrupted, than
it is on the related parental clone CC1/85 cl.7. However, the
IC9564 binding sites on the Env complexes of D1/85.16 cl.23 and
its related parental clone CC1/85 cl.6 are much less exposed, or
are less relevant to entry. As the V3 sequences of D1/85.16 cl.23
and CC1/85 cl.6 are identical to that of CC1/85 cl.7, sequence
differences elsewhere in Env must be responsible for the ,100 fold
differences in IC9564 sensitivities between the first two and the last
(Table 2).
CC101.19 cl.7 has increased sensitivity to V3 MAbs
The increased sensitivity of CC101.19 cl.7 to IC9564 suggests
that its V3 region may also have become more accessible to MAbs.
We have shown that several V3 MAbs (447-52D, F425-B4e8 and
39F) lacked significant neutralizing activity against the CC1/85
parental isolate and both VVC-resistant isolates [31]. Since D1/
85.16 has the same consensus V3 sequence as CC1/85, this
finding suggested that the V3 region of D1/85.16 remained
shielded from NAbs, just as it is on most primary isolates.
However, the V3 region of CC101.19 contains four sequence
changes compared to CC1/85, specifically K305R, H308P,
A316V and G321E (Fig. 1C). Variation of this magnitude could
directly affect the binding sites for MAbs, limiting their value as
probes for V3 accessibility. Indeed, we showed that the four
sequence changes destroyed the epitope for V3 MAb 39F on
gp120 derived from CC101.19, as assessed by a gp120-capture
ELISA [31]. Using the same assay, we found that the V3 epitopes
for MAbs F2A3 and C011 were also lost from CC101.19 gp120
compared to CC1/85 cl.7 gp120, and from the corresponding V3
peptide (data not shown). The epitopes for V3 MAbs 19b, 2.1e,
447-52D and F425-B4e8 were, however, still present on
CC101.19 cl.7 gp120 (Fig. 8). Indeed, the binding of MAb 19b
to gp120 from CC101.19 cl.7 was markedly greater than to the
other three gp120s (Fig. 8A). In contrast, although the V3 MAbs
2.1e, 447-52D and F425-B4e8 did bind detectably to CC101.19
cl.7 gp120, they did so to greatly reduced extents compared to the
gp120 from the other three viruses (Fig. 8B,C,D). Note that each
MAb bound equally well to the gp120s from the two parental
clones and D1/85.16 cl.23 (Fig. 8). This observation is consistent
with these three gp120s having isogenic V3 sequences (Fig. 1C).
We also tested the binding of the MAbs to peptides based on the
V3 sequences of CC1/85 cl.7 and CC101.19 cl.7 (Fig. 8, panel
insets). For 19b, the peptide-binding and gp120-binding data were
consistent, in that the MAb recognized the CC101.19 cl.7
sequences better than CC1/85 cl.7 (Fig. 8A). This was not the
case, however, with MAbs 2.1e, 447-52D and F425-B4e8;
compared to the CC1/85 cl.7 ligands, 2.1e and 447-52D bound
Figure 3. Schematic representation of CCR5 showing positions of amino acid changes in mutant panel. The locations of the NT and the
extracellular loops are indicated. Residues altered in the various mutants are highlighted and labelled, and the positions of the critical sulfated
tyrosine moieties in the NT are also shown. Bars at the Cys residues represent potential disulfide bonds between C101 and C178 and between C20
and C269, which are important for maintaining CCR5 in the correct conformation.
doi:10.1371/journal.ppat.1000548.g003
Entry of HIV Variants Resistant to CCR5 Inhibitors
PLoS Pathogens | www.plospathogens.org 5 August 2009 | Volume 5 | Issue 8 | e1000548more strongly to the CC101.19 cl.7 peptide but less well to the
corresponding gp120, whereas F425-B4e8 bound equally well to
both peptides but poorly to CC101.19 cl.7 gp120. Hence the four
sequence differences between CC1/85 cl.7 and CC101.19 cl.7
affect the epitopes for different V3 MAbs to different extents when
the these epitopes are presented in different contexts (i.e., peptide
vs. gp120).
We therefore tested the neutralization activity of V3 MAbs
19b, 2.1e, 447-52D and F425-B4e8 against the four clonal
infectious viruses. The resulting data pattern for three of the
MAbs was similar to that observed using IC9564. Thus,
CC101.19 cl.7 was markedly the most sensitive of the four
clones to MAbs 19b, 2.1e and 447-52D (Fig. 9A,B,C; Table 3).
Compared to the related parental clone CC1/85 cl.7, the IC50
differentials ranged from ,6-fold for 447-52D to ,30-fold for
19b and 40-fold for 2.1e (Table 3). However, CC101.19 cl.7 was
no more sensitive than CC1/85 cl.7 to MAb F425-B4e8, with an
IC50 differential of ,2-fold (Fig. 9D, Table 3). The increased
neutralization sensitivity of CC101.19 cl.7 to 2.1e and, to a lesser
extent, 447-52D, was particularly striking given the reduced
binding of these MAbs to the corresponding gp120s (compare
Figs. 8 and 9). Presumably, the four sequence changes must
i n c r e a s et h ee x p o s u r eo ft h eV 3r e g i o na tt h eq u a t e r n a r y
structural level (i.e., on the CC101.19 cl.7 virus) to an extent that
is more than sufficient to overcome any locally adverse impact
they may have on the epitope itself (i.e., on gp120). Of note is that
the V3 peptide-binding profiles were a better neutralization
predictor than the gp120-binding profiles for MAbs 2.1e, 447-
52D and F425-B4e8.
In contrast to CC101.19 cl.7, both D1/85.16 cl.23 and the
related parental clone CC1/85 cl.6 were highly resistant to V3
MAbs 19b, 2.1e and 447-52D (Fig. 9A,B,C; Table 3). CC1/85
Table 1. Effect of CCR5 mutations on entry of parental and resistant Env-pseudotyped viruses*.
CC1/85 cl.7 CC101.19 cl.7 CC1/85 cl.6 D1/85.16 cl.23
CCR5-WT 100 100 100 100
NT D18 0 0 0 0
Q4A 84611 90697 2 647 5 615
P8A 67647 6 610 57626 6 616
I9T 89616 86617 94658 1 62
Y10A 80618 2066 60646 0 613
D11A 38612 18675 0 634 1 65
N13A 71667 3 611 74657 0 621
Y14A 38620 62616 9 66
Y14F 55611 160 61647 3 621
Y14Q 6869 20611 90669 9 626
Y10A/Y14A 9661 601 9 613 5 61
S17A 76686 5 688 4 648 9 68
P19A 70636 9 646 4 605 8 68
C20A 5668 2669 70627 4 614
TM2/ECL1 Q93A 76638 2 615 66646 6 68
ECL2 K171A 116641 0 4 639 2 62 10569
E172A 88656 9 657 5 628 6 62
H175A 86612 94612 83628 1 618
C178A 14642 8 682 0 612 9 66
S179A 93688 9 669 0 611 9164
S180A 100619 3 629 2 639 5 67
H181A 80685 4 656 8 655 8 68
F182A 51620 27664 6 652 8 616
P183A 58615 3761 5968 3168
YSQ184-186AAA 59611 62655 2 615 5 61
Q186A 97610 98627 115668 4 613
YQF187-189AAA 95620 95616 89612 8362
Y187A 57686 1 665 6 65 3765
F189A 43624 6 634 0 653 0 61
F193A 65613 59611 6866 49620
Q194A 106671 0 3 616 100679 9 66
*The values recorded are the relative entry efficiencies of the CC1/85 cl.7, CC101.19 cl.7, CC1/85 cl.6 and D1/85.16 cl.23 Env-pseudotyped viruses into U87-CD4 cells
transiently expressing (for 48 h) the CCR5 proteins indicated. Luciferase expression was measured 72 h after infection, and is normalized relative to the entry of each
virus via WT CCR5 (defined as 100%). Each value is the mean6SEM of at least three independent determinations. A 50% decrease in entry efficiency was considered to
be meaningful in this assay, so all values #50% are bolded. It is possible that lesser decreases (e.g., 30–50%) might also be biologically relevant.
doi:10.1371/journal.ppat.1000548.t001
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CC1/85 cl.7, to neutralization by MAb F425-B4e8, which was
the only V3 MAb able to neutralize D1/85.16 cl.23 (Fig. 9D).
Given that the V3 sequences of these three clones are identical
( F i g .1 C ) ,a n dt h a tF 4 2 5 - B 4 e 8b inds comparably to all three
gp120s (Fig. 8D), quaternary structural differences in the native
Env complexes must again be responsible for the neutralization
sensitivity differences.
Taken together, the inference of the above experiments is that
the V3 region of CC101.19 cl.7 has become unusually accessible
to antibodies and a small molecule ligand, even compared to
CC1/85 cl.7. In contrast, the V3 region is poorly exposed on
CC1/85 cl.6 and on D1/85.16 cl.23, with the exception that the
F425-B4e8 epitope is accessible on the latter virus. The two VVC-
resistant viruses have therefore taken routes to resistance that not
only differ at the genetic level, but also at the phenotypic.
Figure 4. Sensitivity of parental and VVC-resistant clones to inhibitors of the gp120-CD4 interaction. Chimeric molecular clones CC1/85
cl.7 (squares), CC1/85 cl.6 (diamonds), CC101.19 cl.7 (triangles) and D1/85.16 cl.23 (circles) were used to infect PBMCs in the presence of the indicated
concentrations of (A) sCD4, (B) MAb b12, (C) MAb RPA-T4 or (D) BMS-806. Of these compounds, sCD4, b12 and BMS-806 bind to gp120, RPA-T4 to
CD4, but each of them inhibits gp120-CD4 binding. The data represent the extent of inhibition of replication (p24 antigen production) relative to that
in the absence of inhibitor (100% replication, 0% inhibition). The data points in all panels are mean values6SEM from 3 independent experiments.
doi:10.1371/journal.ppat.1000548.g004
Table 2. IC50 values for inhibition of parental and resistant clones and isolates by gp120-targeting compounds.
Clones Isolates
CC1/85 cl.7 CC101.19 cl.7 CC1/85 cl.6 D1/85.16 cl.23 CC1/85 CC101.19 D1/85.16
sCD4
* 0.1060.035 0.1060.027 .25 1060.058 .10 .10 .10
CD4-IgG2 (PRO542)
* 0.1260.045 0.160.017 ND 860.95 4.761.6 6.261. 7 2.660.90
BMS-806
{ 4064.2 2161.3 1.560.40 2.060.12 2062.0 3066.1 3.061.7
IC9564
{ 7.262.6 0.6260.10 150610 690686 300612 17064.3 1700644
*IC50 values are expressed in mg/ml.
{IC50 values are expressed in nM.
ND=Not done.
All IC50 are mean of 3 independent experiments6SEM.
Values in bold indicate that IC50 is significantly different (at least 5-fold) than that of CC1/85 cl.7 (for the clones) and CC1/85 (for the isolates).
doi:10.1371/journal.ppat.1000548.t002
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NAbs
To create additional antibody probes for studying CC101.19
cl.7, we immunized rabbits (two per group) with 34-residue V3
peptides derived from this virus and also from CC1/85 cl.7, which
has the same V3 sequence as CC1/85 cl.6 and D1/85.16 cl.23
(Supporting Information, Text S1). Both V3 peptides were
immunogenic in rabbits, inducing antibodies that bound to the
cognate and, to a lesser extent, non-cognate, peptide and gp120 in
ELISA (Supporting Information; Figs. S1 and S2).
The rabbit anti-V3 sera were then tested for neutralizing activity
against the Env-pseudotyped clonal viruses in U87-CD4-CCR5 cells.
None of the four antisera neutralized CC1/85 cl.7, CC1/85 cl.6 or
D1/85.16 cl.23 (Fig. 10). However, CC101.19 cl.7 was specifically
neutralized by the two antisera raised against the autologous V3
peptide (Fig. 10C). Hence the V3 sequence changes that drive VVC
resistance have not only caused the V3 region of the CC101.19 Env
complex to become more accessible to neutralizing antibodies, they
have also created a neo-epitope for the induction of such antibodies.
Depicting the V3 sequence changes on the V3 structure
To assess how the V3 sequence differences between CC1/85
cl.7 and CC101.19 cl.7 may affect the tertiary structure of V3 in
the context of gp120, we introduced the two gp120 sequences into
two different X-ray crystal structures of a V3-containing gp120
core [9,10,43], and then superimposed the resulting models
(colored red and yellow, respectively in Fig. 11A,B). In the first
template, gp120 is bound to sCD4 and MAb X5 that, like 17b and
48d, binds to the CD4i epitope cluster overlapping the CCR5
binding site [9]. The second template was based on a gp120 core
bound to both sCD4 and the tyrosine-sulfated 412 MAb that
mimics the CCR5 NT [10]. We elected to use both templates,
because unlike template 1, template 2 may mimic the interaction
with the tyrosine-sulfated CCR5 NT. The comparison might be
informative for understanding why CC101.19 cl.7 has become
more dependent on the latter interaction.
Although the gp120 structures align well, the V3 domains
assume different structures in the two templates (Fig. 11A,B). In
template 1, V3 protrudes from the gp120 core and has three
distinct structural regions: (i) a conserved base connected by a
disulfide bridge. This b-sheet is part of a 6-stranded b-barrel that
forms the core of the gp120 outer domain [45]; (ii) a flexible stem
that extends away from the core; and (iii) a b-turn tip (Fig. 11B). In
template 2, the tyrosine-sulfated residues bind to the bridging
sheet-V3 interface and induce a structural rearrangement in V3
(Fig. 11B). As a result, the N- and C-terminal constituents of the
Figure 5. Binding of CD4-IgG2 and MAb 17b to monomeric gp120. Equal amounts of gp120 from viral lysates were captured by D7324 onto
an ELISA plate and incubated with (A) CD4-IgG2; (B) CD4-IgG2 (0.4 mg/ml) plus increasing concentrations of the competitor, BMS-806; (C) MAb 17b in
the absence or presence of sCD4 (300 ng/ml); (D) MAb 17b (0.4 mg/ml) plus increasing concentrations of the competitor, BMS-806. (A, C) The OD450
values shown were corrected for background binding of CD4-IgG2 and 17b, respectively, as measured in the absence of gp120. (B, D) The data shown
represent the percentage inhibition of binding of CD4-IgG2 and 17b, respectively, in the presence of the indicated concentrations of BMS-806, with
0% inhibition (100% binding) occurring when BMS-806 was absent. The data points in each panel were derived from a single representative
experiment.
doi:10.1371/journal.ppat.1000548.g005
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that replaces the unstructured V3 stem from the first template. In
addition, the V3 tip is displaced by 16 A ˚ (Fig. 11B).
We then inspected where the V3 amino acid changes between
CC1/85 cl.7 and CC101.19 cl.7 were located on the two
templates (Fig. 11D–F). Two of the substitutions in CC101.19
cl.7, K305R and G321E, are on opposite strands of the b-sheet
that is present in the gp120 complex with the tyrosine-sulfated
412d MAb (template 2) but not in the X5 complex (template 1).
Both these changes increase the local propensity for forming a b-
sheet (Gly, in particular, is accommodated poorly in b-sheets).
Moreover, the E321 and R305 side chains in the CC101.19 cl.7
V3 protrude from the same lateral side of the b-sheet and are
positioned close enough to form a salt-bridge that could contribute
to inter-strand stability. Although the model was based on a V3
conformation derived from a CD4-bound gp120 model, it is
possible that a salt bridge could form between E321 and R305,
prior to gp120 engagement with CD4 or CCR5. Circular
dichroism experiments suggest that a CC101.19 cl.7 V3 peptide
has more secondary structure than the corresponding peptide from
CC1/85 cl.7 (our unpublished observations). Moreover, and as
noted previously, the H308P may facilitate a bend in the V3
structure of CC101.19 cl.7 [20], which may contribute to a
relocation of the V3 tip and affect its ability to interact with
CCR5.
Thus, the characteristics of the amino acid changes and the
available structural data are consistent with a model, based on
template 2, in which the CC101.19 cl.7 V3 region constitutively
assumes a stabilized conformation that is compatible with binding
to the Tyr-sulfated CCR5 NT. In this conformation, the V3
region is more structured, accommodating the binding of the
tyrosine-sulfate moieties while at the same time displacing its V3
tip away from the CCR5 ECL2. Whether this model is valid is the
subject of ongoing experimental and structural studies.
Mapping V3 MAb epitopes on the V3 structure
To assist the interpretation of the V3 MAb binding experi-
ments, we mapped the epitopes for MAbs 447-52D, 2.1e, F425-
B4e8 and 19b on the V3 crystal structures represented by
templates 1 and 2 (Fig. 11G). Note that the available crystal
structures for 447-52D and F425-B4e8 with their peptide V3
epitopes reveal more contact residues than are indicated here
[46,47]. However, we choose to focus on the more essential
residues revealed by phenotypic analyses [48–50]. MAbs 447-52D
and 2.1e bind primarily to the V3 tip, although their requirements
are subtly different. The essential residues for F425-B4e8 are
immediately adjacent to the tip, while 19b also requires residues in
the stem. If our interpretation of Fig. 11 is correct, MAbs 19b,
447-52D and 2.1e, but not F425-B4e8, may preferentially
recognize the V3 configuration represented by the right-hand
panels in Fig. 11G.
Discussion
Our goal in this study was to learn more about how HIV-1 Env
interacts with the CCR5 co-receptor. We used two different but
genetically related viruses, CC101.19 and D1/85.16, which have
become resistant to small molecule CCR5 inhibitors such as VCV,
AD101 and maraviroc. Both resistant variants still use CCR5 for
entry, but they have acquired the ability to recognize the inhibitor-
CCR5 complex as well as the free co-receptor; their parental
strain, CC1/85, can only use free CCR5 for entry and is,
therefore, sensitive to small molecule CCR5 inhibitors [18]. Of
note is that although both variants share the resistance phenotype,
they have taken different genetic routes to it; thus CC101.19 has
four amino acid changes in the V3 region of gp120 whereas D1/
85.16 has three substitutions in the gp41 fusion peptide [20,22].
Additional changes elsewhere in Env may contribute to the
replication capacity of each virus, but they are neither necessary
Figure 6. Sensitivity of parental and VVC-resistant clones to
MAbs against the CD4i epitope cluster. Chimeric molecular clones
CC1/85 cl.7 (squares), CC1/85 cl.6 (diamonds), CC101.19 cl.7 (triangles)
and D1/85.16 cl.23 (circles) were used to infect PBMCs in the presence
of the indicated concentrations of (A) MAb 48d or (B) MAb 17b. The
data represent the extent of inhibition of replication (p24 antigen
production) relative to that in the absence of inhibitor (100%
replication, 0% inhibition). The data points are mean values6SEM from
3 independent experiments.
doi:10.1371/journal.ppat.1000548.g006
Figure 7. Sensitivity of parental and VVC-resistant clones to
the small molecule, V3-targeted inhibitor IC9564. Chimeric
molecular clones CC1/85 cl.7 (squares), CC1/85 cl.6 (diamonds),
CC101.19 cl.7 (triangles) and D1/85.16 cl.23 (circles) were used to infect
PBMCs in the presence of the indicated concentrations of IC9564. The
data represent the extent of inhibition of replication (p24 antigen
production) relative to that in the absence of inhibitor (100%
replication, 0% inhibition). The data points are mean values6SEM from
3 independent experiments.
doi:10.1371/journal.ppat.1000548.g007
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these other sequence changes have any influence on any of the
phenotypes described here. By studying how these two viruses
accomplished the same task in such radically different ways, we
reasoned that we might learn something useful about inter-domain
interactions within the HIV-1 Env complex. For example, do
changes in the fusion peptide have the same effect on Env topology
as ones in the V3 region of an entirely different subunit?
We used infectious chimeric viruses and Env-pseudotyped
viruses based on clones from the parental and each resistant
isolate. The CC1/85 parental isolate was derived from an HIV-1
infected individual who had been infected for at least five years
[51,52]. Accordingly, CC1/85 contains diverse quasispecies. Here,
we studied two different clones (cl.6 and cl.7) derived from the
CC1/85 isolate, and one clone from each resistant isolate, i.e.
CC101.19 cl.7 and D1/85.16 cl.23. The phenotypic properties of
these clones are summarized in Table S1. A multiple sequence
alignment analysis showed that the amino-acid sequence of CC1/
85 cl.6 is more related to that of D1/85.16 cl.23 whereas CC1/85
cl.7 more resembles CC101.19 cl.7, although it is not possible to
prove evolutionary relationships. Of note is that CC1/85 cl.7 is
much more sensitive than CC1/85 cl.6 to sCD4, the V3-targeting
compound IC9564 and NAbs against V3. Thus, CC1/85 cl.7
behaves more like a T-cell line-adapted virus than a primary virus
in this regard. The genetic determinants of this clone’s sensitivity
to NAbs and CD4-targeted inhibitors must lie outside its V3
region, which is identical to those of the more resistant clones
CC1/85 cl.6 and D1/85.16 cl.23.
This atypical phenotype of CC1/85 cl.7 underlies its use as a
comparator virus for CC101.19 cl.7, which is also unusually sCD4-
sensitive. Although we cannot exclude the possibility that this
property of CC101.19 cl.7 is relevant to its VVC-resistance
phenotype, we strongly suspect otherwise. Instead, we think that
CC101.19 cl.7 evolved from a sCD4-sensitive parental virus that
shares certain Env characteristics with CC1/85 cl.7. The parental
virus for D1/85.16 cl.23 was, in contrast, probably one of the more
prevalent sCD4-resistant variants that resemble CC1/85 cl.6.
Passage of HIV-1 primary isolates creates sCD4 sensitivity not only
inT-celllines[34,53] butalsoinPBMC[32].Thus,whentheCC1/
85 parental isolate was cultured in primary CD4
+ T cells for 19
passages in the absence of any selecting compound, as a control for
AD101-selection pressure, the resulting CCcon.19 isolate was
substantially more sensitive to sCD4 and MAb b12, but not to
several other MAbs and inhibitors that target other Env regions
[32]. The genetic determinants of the sCD4 sensitivity of CCcon.19
lay within the gp120 V2 loop: substitutions I165K and D167N, and
an SN deletion at positions 188–189 [32]. Clones CC1/85 cl.7,
CC101.19 cl.7 and D1/85.16 cl.23 all have the D167Nsubstitution,
but CC1/85 cl.6 does not, while the I165K substitution and the SN
deletion at positions 188–189 were absent from all four clones (data
Figure 8. Binding of V3 MAbs to gp120 monomers and V3 peptides. The titration curves represent the binding of gp120 from viral lysates of
CC1/85 cl.7 (squares), CC1/85 cl.6 (diamonds), CC101.19 cl.7 (triangles) and D1/85.16 cl.23 (circles) to MAbs (A) 19b; (B) 2.1e; (C) 447-52D; (D) F425-
b4e8. MAb binding (OD450 values) was corrected for background binding in the absence of gp120. The data points show the results of one
representative experiment. The inset panels show the binding of the same MAbs to V3 peptides derived from CC1/85 cl.7 (solid squares) and
CC101.19 cl.7 (solid triangles).
doi:10.1371/journal.ppat.1000548.g008
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explain the marked difference in sCD4 sensitivity between the two
parentalclones[32].Most oftheaminoacid differencesbetweenthe
comparator pairs (CC1/85 cl.7 vs. CC101.19 cl.7 and CC1/85 cl.6
vs. D1/85 cl.23) lie within the V4 and V5 regions (Fig. 1B). Of note
is that the differences in sCD4 sensitivity between the various
parental and resistant clones were not attributable to variation in
binding of the gp120 monomer to CD4. Thus, as is usually the case,
the efficiency of sCD4 neutralization is determined by the
quaternary structure of the native Env complex [33,36,37].
The BMS-806 sensitivity profiles of the parental and resistant
clones (and isolates) were the inverse of those seen using sCD4,
which is consistent with a previous report [54]. Thus D1/85.16
cl.23 was simultaneously the clone most resistant to sCD4 but the
most sensitive to BMS-806, and conversely for CC101.19 cl.7.
However, as seen with sCD4, BMS-806 sensitivity also varied
markedly between the two parental clones; CC1/85 cl.6 behaved
akin to D1/85.16 cl.23 while CC1/85 cl.7 again resembled
CC101.19 cl.7. Moreover, the pattern of infection-inhibition data
for BMS-806 and the four clones was reflected in the outcome of a
gp120-CD4 inhibition assay using the corresponding monomeric
gp120s. Hence, as with sCD4 sensitivity, we do not believe the
different responses of the various clones to BMS-806 are causally
related to CCR5 inhibitor resistance. The increased BMS-806
sensitivity of CC1/85 cl.6 and D1/85.16 cl.23 compared to the
other two clones may simply reflect how gp120 sequence variation
affects BMS-806 binding, although none of the four clones
contained any amino acid changes known to be associated with
BMS-806 resistance [55].
The current model of how gp120 interacts with CCR5 posits
that two different structural elements of each protein are involved:
the tip of V3 region of gp120 binds to ECL2 of CCR5, the base
and stem of V3 and the bridging sheet to the NT [8–12]. To allow
multi-point attachment, the twin-elements of each protein must be
folded into an appropriate geometry. It seems a reasonable
assumption that the binding of a small molecule inhibitor alters the
orientation between the ECL2 and NT regions, disrupting the
multi-point binding site for gp120 and thereby impeding the
gp120-CCR5 interaction. Hence the simplest hypothesis for how
Figure 9. Sensitivity of parental and VVC-resistant clones to V3 MAbs. Chimeric molecular clones CC1/85 cl.7 (squares), CC1/85 cl.6
(diamonds), CC101.19 cl.7 (triangles) and D1/85.16 cl.23 (circles) were used to infect PBMCs in the presence of the indicated concentrations of (A)
MAb 19b; (B) MAb 2.1e; (C) MAb 447-52D; (D) MAb F425-B4e8. The data represent the extent of inhibition of replication (p24 antigen production)
relative to that in the absence of inhibitor (100% replication, 0% inhibition). The data points are mean values6SEM from 3 independent experiments.
doi:10.1371/journal.ppat.1000548.g009
Table 3. IC50 values for inhibition of parental and resistant
clones by V3 MAbs.
CC1/85 cl.7 CC101.19 cl.7 CC1/85 cl.6 D1/85.16 cl.23
19b 1.160.40 0.03660.018 .100 .100
2.1e 1764.0 0.4560.058 .100 .100
447-52D 3161.6 5.560.50 .100 .100
F425-B4e8 1.960.37 1.460.13 .100 9.461.0
All IC50 values are expressed in mg/ml and are mean of 3 independent
experiments6SEM.
doi:10.1371/journal.ppat.1000548.t003
Entry of HIV Variants Resistant to CCR5 Inhibitors
PLoS Pathogens | www.plospathogens.org 11 August 2009 | Volume 5 | Issue 8 | e1000548the resistant viruses recognize both the inhibitor-bound and –free
forms of CCR5 is that they use a single-point attachment
mechanism. In other words, their Env complex interacts with
either ECL2 or the NT, and does so in a way that is unaffected, or
little affected, by a small molecule CCR5 inhibitor. Our
experiments with CCR5 point-mutants were designed to test this
hypothesis. We observed that the two escape mutants do indeed
differ in their usage of ECL2 and the NT, when compared both to
each other and to parental clones. Thus, CC101.19 cl.7 was highly
dependent on residues in the CCR5 NT, namely Y10, Y14 and
C20; in contrast, D1/85.16 cl.23 was markedly less affected by
changes in the NT but was slightly more sensitive to some ECL2
substitutions (Table 1). It is also noteworthy that CC101.19 cl.7
and CC1/85 cl.7 were comparably sensitive to some ECL2
mutations. Overall, both resistant viruses were somewhat less
tolerant of CCR5 mutations than their comparator clones, which
may reflect their acquired capacity to also use the inhibitor-CCR5
complex. That constraint might reduce the robustness and
promiscuity of the normally rather plastic Env-CCR5 interaction;
we have hypothesized that resistant viruses preferentially use
certain conformational subspecies or isoforms of both free and
inhibitor-complexed CCR5 [22].
We next used MAbs and a small molecule that interact with the
different elements of the CCR5 binding site on gp120, as additional
probes of differences in the CCR5 interactions of the two resistant
clones. The VVC-resistant clone CC101.19 cl.7 was markedly the
most sensitive of the four clones to five different MAbs against the
CD4i epitope cluster on gp120 that is an important element of the
CCR5 binding site, the bridging sheet. The sensitivity of CC101.19
cl.7 to CD4i MAbs was significantly greater than its comparator
parental clone CC1/85 cl.7, suggesting it was relevant to the VVC-
resistance phenotype and not just a general property of this
particular clonal lineage. Of note is that the binding of CD4i MAbs
to the various gp120 proteins was not correlated with how the same
MAbs neutralized the corresponding viruses. Hence the increased
neutralization sensitivity of CC101.19 cl.7 to CD4i MAbs must be
determined by the quaternary structure of the native Env trimer, not
the topology of the gp120 monomer. Overall, we suggest that at least
one major element of the CCR5 binding site, the CD4i epitope
cluster, has become constitutively exposed on the native Env
complex of CC101.19 cl.7. Alternatively, the geometry of the
interaction between the mutant Env complex and the target cell
surface may be one in which the normal steric constraint on the
binding of CD4i NAbs has become relaxed. However, D1/85.16
cl.23 remains highly resistant to CD4i MAbs, irrespective of whether
they are tyrosine-sulfated (47e, 412d, CM51 and E51) or not (48d
and 17b), implying that the fusion peptide changes and the V3
changes affect Env topology differently.
The IC9564 small molecule binds to positively charged residues
in the V3 stem, N-terminal to the tip. It competes with MAbs 39F
and 447-52D that target the same region [42]. However, IC9564
resistance is associated with amino acid changes in the bridging
Figure 10. Neutralization of parental and VVC-resistant clones by rabbit anti-V3 peptide sera. Anti-peptide sera (day 49) from rabbits R1
(V3-CC1/85; closed squares), R2 (V3-CC1/85; closed circles), R3 (V3-CC101.19; open squares) and R4 (V3-CC101.19; open circles) were tested for their
neutralizing activity against entry of Env-pseudotyped viruses (A) CC1/85 cl.7; (B) CC1/85 cl. 6; (C) CC101.19 cl.7; (D) D1/85 cl.23 into U87-CD4-CCR5
cells. The percent neutralization by immune sera was normalized to the effect of the pre-immune sera at the corresponding dilution. In most case, the
effect of pre-immune sera on viral entry was negligible. The values shown are the means6SEM from two independent experiments.
doi:10.1371/journal.ppat.1000548.g010
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lock gp120 into a CD4-induced conformation in which CD4i
epitopes become more exposed [43]. We observed that CC101.19
cl.7 was the most sensitive of the four clones to IC9564, again
significantly more so than the comparator parental clone, CC1/85
cl.7. Hence either the V3 binding site for IC9564 is significantly
more accessible on CC101.19 cl.7 than on CC1/85 cl.7, or the
interaction between the V3 region of CC101.19 cl.7 and the
CCR5 NT is more vulnerable to disruption by the small molecule
ligand. In comparison, D1/85.16 cl.23 and CC1/85 cl.6 were
highly resistant to IC9564. Because the V3 sequences of D1/85.16
cl.23 and CC1/85 cl.7 are identical, sequence changes elsewhere
in Env must underlie the ,100-fold difference in their IC9564
sensitivities, presumably by affecting how well its V3 binding site is
exposed on the Env complex.
Similar results were obtained using several MAbs to the V3
region of the four clones. Again, CC101.19 cl.7 was markedly the
most sensitive virus, even compared to CC1/85 cl.7. This is
particularly remarkable given that the four sequence changes in its
region V3 actually reduce the binding of some of the MAbs to the
corresponding gp120 monomer (and destroy the epitopes for other
V3 MAbs). Taken together with the data on IC9564 sensitivity,
these observations suggest that the V3 region of CC101.19 cl.7 is
well exposed on the native Env complex. But, as with the CD4i
epitope cluster, this is not the case with D1/85.16 cl.23; the V3
region of this clone remains sequestered, perhaps even more so
than on the comparator parental clone. The increased exposure of
V3 on CC101.19 cl.7 Env presumably facilitates interactions with
the CCR5 NT, but a side effect is to render the virus highly
sensitive to NAbs that target V3. Other studies have also shown
that deletions or other radical changes in V3 disrupt the
interaction between this region of gp120 and ECL2 of CCR5,
and thereby render HIV-1 more dependent on the CCR5 NT for
binding and entry [56,57].
In summary, we propose that the structural change created by
the four amino acid substitutions in CC101.19 cl.7 impairs the
interaction of the V3 tip with ECL-2, while promoting the binding
of the V3 base and bridging sheet to the NT; the latter outcome
would account for the increased dependence of CC101.19 cl.7 on
sulfated tyrosine residues 10 and 14 and its enhanced sensitivity to
MAbs that bind to CD4i epitopes associated with the bridging
sheet. We have depicted the four sequence changes on the
conformation of V3 in the context of the gp120 monomer, using
structural templates that may represent the V3 structures that exist
Figure 11. Mapping sequence changes on V3 structures. (A) The CC101.19 cl.7 and CC1/85 cl.7 gp120 structures were modelled with Swiss-
Model (http://swissmodel.expasy.org) using template 1 (2B4C.pdb; red) or template 2 (2QAD.pdb; yellow) and superimposed using Pymol (http://
www.pymol.org) with a root-mean-square deviation (RMSD) value of 0.892. All the V3 conformations illustrated in this figure are derived from the
CD4-bound form of gp120, and differ from the conformation of the unligated form. The box in (A) encloses the V3 region, which is shown in more
detail in (B). The residues that differ between the two sequences are colored red (CC1/85 cl.7) or yellow (CC101.19 cl.7) in the V3 models derived using
template 1 (C and E) and template 2 (D and F). Note that, in template 2 (F), residues Arg-305 and Glu-321 are positioned close enough together to
form a strand-stabilizing salt-bridge. (G) Depiction of the MAb epitopes on the V3 surface. Key contact residues are colored as follows: 447-52D:
residues 312, 313 and 315 (green) [48]; 2.1e: residues 313, 314, 315, 316 and 317 (magenta) [49]; F425-B4e8: 309, 315 and 317 (yellow) [50]; 19b:
residues 304, 307, 313, 315, 317 and 318 (red) [50]. The V3 templates and models used were the same as shown in Fig. 11 (C,D) and are based on the
CC1/85 cl.7 sequence; basing them instead on the CC101.19 cl.7 sequence was not visually informative and the outcome is not depicted.
doi:10.1371/journal.ppat.1000548.g011
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outcome of the model is that, in the CD4-bound form of gp120
(template 2), the K305R and G321E changes may create an inter-
strand salt-bridge that stabilizes this V3 configuration in
CC101.19 cl.7 Env and perhaps facilitates its interaction with
the CCR5 NT. Furthermore, the H308P change introduces a kink
into the V3 region that may affect the geometry of the tip and
impair its ability to interact with ECL2. These suppositions are, of
course, speculative pending additional structural information.
A similar substitution pattern, R305K+G321E, at the same V3
residues occurred when escape mutants to VVC emerged in a
different viral context in vivo [13]. The R305K change is the inverse
of what happens in CC101.19 cl.7, but preserves a cationic residue
at this position; the G321E substitution is identical to the one arising
in CC101.19 cl.7 and introduces an anionic amino acid. Perhaps in
the different genetic contexts, the two changes together create the
same salt bridge and have the same effect of stabilizing a V3
conformation that is better able to interact with the CCR5 NT.
Therewere differences betweenthe variousV3 MAbsinhowthey
neutralized the various clones, and in how they bound to the
corresponding gp120s and V3 peptides. Of particular note is that
MAb 19b bound markedly better to gp120 and the V3 peptide from
CC101.19 cl.7, and neutralized the corresponding virus much more
potently, compared to the other gp120s, peptide and viruses. Thus
the four sequence changes that created CCR5 inhibitor resistance
must have had a substantial effect on the topology of at least part of
the V3 region of CC101.19 cl.7 that is apparent at the levels of both
the gp120 monomer and a simple V3 peptide. MAbs 2.1e, F425-
B4e8 and 447-52D, however, bound less well to CC101.19 cl.7
gp120, but still neutralized the corresponding virus more potently
than the comparator clone, CC1/85 cl.7. The IC50 differentials
between CC101.19 cl.7 and CC1/85 cl.7 also varied from MAb to
MAb, being much lower for F425-B4e8 and 447-52D than for 19b
and 2.1e. Some sub-regions of V3 may therefore be more exposed
than others on the CC101.19 cl.7 Env complex. Consistent with this
idea, the epitopes for 19b, 2.1e, 447-52D and F425-B4e8 are located
in different regions of V3. The X-ray crystal structure of the 447-
52D complex with a V3 peptide shows that the side chains of six
amino acid residues upstream of the GPGR turn are arranged into a
b-hairpin and form a b-sheet with the side chains of a corresponding
strand of the MAb [58]. F425-B4e8, on the other hand, interacts
with the V3 crown, particularly with Arg-315 [47]. Of note is that
F425-B4e8 was the only V3 MAb able to neutralize D1/85.16 cl.23,
so perhaps the region around Arg-315 is the only part of V3 exposed
on D1/85.16 cl.23, and hence accessible to F425-B4e8. Structural
information is not available for 19b and 2.1e, but mutagenesis and
phage display data suggest that 19b recognizes flanking region in V3
upstream to the crown while 2.1e sees elements of the crown and
downstream flanking residues [49,50,59]. If our interpretation of the
V3-gp120 modelling data is correct, then MAbs 19b (in particular),
447-52D and 2.1e, but not F425-B4e8, may preferentially recognize
the V3 configuration that is stabilized by the salt bridge between
Arg-305 and Glu-321 in CC101.19 cl.7 gp120.
The V3 region of CC101.19 cl.7 is also a neo-epitope, in that a
peptide containing the four amino acid changes was immunogenic
in rabbits, inducing Abs that were able to neutralize the
corresponding virus via its exposed V3 region. We reported
previously that both the CC101.19 and D1/85.16 isolates are
more sensitive than the parental isolate to various anti-Env MAbs
and sera from HIV-1 infected people, albeit usually not to a
dramatic extent [31]. The present results confirm and extend those
findings. Hence, variants that arise in vivo under the selection
pressure of maraviroc or VCV might be more vulnerable than
wild type viruses to NAbs raised against both existing and neo-
epitopes on their Env complexes, particularly the V3 region. In
other words, to resist the CCR5 inhibitors, HIV-1 will need to
adapt in a way that also preserves its existing defences against
humoral immunity. The twin constraints on the Env complex
might therefore create variants with interesting and informative
properties. We do not yet know, but are investigating, whether the
increased exposure of V3 and other neutralization epitopes is
obligatorily linked to the sCD4-sensitivity of a subset of parental
clones. The parental isolate was derived from a patient with
chronic HIV-1 infection in whom X4 viruses were detected a year
later and has considerable quasispecies diversity [52]. Its
properties may be relevant, given current clinical practice with
CCR5 inhibitors and the generation of resistance in vivo [60].
Overall, we conclude that the two resistant variants have
adapted to the selection pressure of the small molecule CCR5
inhibitors in different ways, both genetically and phenotypically.
They are similar in that both can use the inhibitor-CCR5 complex
and free CCR5 for entry, but they differ in how they do so. The
four V3 sequence changes in CC101.19 cl.7 have constitutively
exposed elements of the CCR5 binding site on the native Env
complex of this virus, both within V3 and associated with the
CD4i epitope cluster. These changes facilitate interactions of the
Env complex with the tyrosine-sulfated CCR5 NT. It remains a
mystery, however, how the three fusion peptide changes in D1/
85.16 cl.23 render this virus CCR5 inhibitor-resistant. The V3
and bridging sheet elements are no more exposed, and perhaps
even less well exposed, on D1/85.16 cl.23 than on the comparator
parental clone, and there is no compelling evidence from the
CCR5 mutant panel as to how the virus-coreceptor interactions
differ. We note, however, that even mutations in the gp41
cytoplasmic tail can enhance interactions with CCR5, allowing the
mutant virus to infect cells that express only trace amounts of the
coreceptor [61]. Perhaps D1/85.16 cl.23 interacts productively
only with subpopulations of free and liganded CCR5 that are
sometimes available only in limited quantities [22]. The CCR5-
triggered conformational changes in Env that drive fusion may
have different quantitative and qualitative requirements for the
fusion peptide- and cytoplasmic tail-gp41 mutants, compared to
wild type viruses. Additional studies will need to be performed to
address such concepts and thereby enable us to better understand
the D1/85.16 cl.23 resistance mechanism.
Materials and Methods
Cells and cell culture
U87-CD4 and U87-CD4-CCR5 cells, contributed by Dr.
HongKui Deng and Dr. Dan Littman, were obtained from the
NIH AIDS Research and Reference Reagent Program (ARRRP)
[62]. 293T cells were from the American Type Culture Collection
(ATCC; Manassas, VA). All these cell lines were maintained in
Dulbecco’s modified Eagle medium (DMEM; Invitrogen, Carls-
bad, CA), supplemented with 10% fetal bovine serum (FBS;
Invitrogen) and 100 U/ml penicillin+100 mg/ml streptomycin (16
PenStrep; HyClone, Logan, UT) and L-glutamine (Invitrogen).
PBMC were purified from leukopacks obtained from the New
York Blood Center (New York, NY) and stimulated as previously
described [20]. Briefly, the leukopacks were depleted of CD8
+ cells
using the RosetteSep reagent (StemCell Technologies, Vancouver,
BC, Canada) and then purified on a Ficoll density gradient. Cells
from each blood donor were split into two cultures, one of which
was stimulated for three days with surface-immobilized anti-CD3
MAb (clone OKT3), the other with 5 mg/ml of phytohemagglu-
tinin (PHA; Sigma). The PBMC culture medium was RPMI 1640
(Invitrogen) supplemented with 10% FBS, 16 PenStrep and
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La Roche, Inc.). All cells were incubated at 37uC in an atmosphere
containing 5% CO2.
Antibodies and compounds
MAbs 17b, 48d, 19b and 2.1e were gifts from Dr. James
Robinson (Tulane University, New Orleans, LA), MAb b12 from
Dr. Dennis Burton (Scripps Research Institute, La Jolla, CA).
RPA-T4 was purchased from Santa Cruz Biotech, CA. The MAbs
447-52D and F425-B4e8 were obtained through NIH AIDS
Research and Reference Reagent Program, Division of AIDS,
NIAID, NIH, contributed by Dr. S. Zolla-Pazner and Dr. M.
Poster, respectively. sCD4 and CD4-IgG2 were donated by Dr.
William Olson (Progenics Pharmaceuticals, Tarrytown, NY),
BMS-806 by Dr. Richard Colonno (Bristol-Myers Squibb, Wall-
ingford, CT). The gp120-targeting compound IC9564 was
provided by Dr. Chin-Ho Chen (Meharry Medical College,
Nashville, TN). The small molecule CCR5 inhibitor VVC (SCH-
D, SCH-417690) [63] was provided by Dr. Julie Strizki (Schering-
Plough Research Institute, Kenilworth, NJ).
Viruses, gp120 proteins and CCR5 mutants
The construction of the pNLluc-AM and PCI-Env plasmids has
been previously described [18]. In brief, the pNLluc-AM vector
consists of the pNL4-3 proviral plasmid, in which a portion of the
env gene was deleted and replaced with an SV40 promoter/firefly
luciferase cassette using a yeast recombination system [64]. The
pCI-env expression plasmids were constructed by insertion of the
CC1/85 cl.7, CC1/85 cl.6, CC101.19 cl.7 and D1/85.16 cl.23 env
genes into the multiple cloning site of pCI (Promega, Madison,
WI) at the EcoRI-XhoI restriction site. The construction and
properties of clonal viruses pNL4-3/env derived from CC1/85
cl.7, CC1/85 cl.6, CC101.19 cl.7 and D1/85.16 cl.23 have been
previously described [14,18,20].
The PPI4-CC1/85 cl.7 and PPI4-CC101.19 cl.7 gp120
expression plasmids were cloned as previously described [20].
Briefly, KpnI-BbvCI fragments from the desired env gene were
subcloned into the pPPI4-JR-FL gp140 vector [65]. Two
consecutive in-frame stop codons were then introduced by
QuickChange mutagenesis (Stratagene), immediately following
the lysine in the sequence REKR, the natural cleavage site
between gp120 and gp41.
All CCR5 mutants were provided by Dr. Tanya Dragic (Albert
Einstein College of Medicine, Bronx, NY) except for Y10A, Y14F
and Y14Q, which were donated by Dr. David Kabat (Oregon
Health and Science University, Portland, OR).
Virus and pseudovirus preparation
pNL4-3/env plasmids were constructed as previously described
[20,22]. Infectious clonal virus stocks were prepared by transient
transfection of 293T cells with pNL4-3/env plasmids using
Lipofectamine 2000 (Invitrogen, Carlsbad, CA) according to the
manufacturer’s instructions, as described elsewhere [20]. All stocks
of infectious viruses were passed through a 0.45-mm filter and
stored in aliquots at 280uC. The titers (50% tissue culture
infectious dose; TCID50) of all stocks were determined in PBMC
culture by standard methods [66].
Env-pseudotyped viruses were made by co-transfecting 293T
cells with a 3:1 ratio of the plasmids pCI-env and pNLluc-AM,
using Lipofectamine 2000 (Invitrogen) according to the manufac-
turer’s instructions. One day after transfection, the cells were
washed with culture media and incubated for one additional day.
The virus-containing supernatants were passed through a 0.45-mm
filter immediately before use.
Sequence analysis
To determine similarities between amino acid sequences, a
Clustal W multiple sequence alignment (MSA) of Env amino acid
sequences was generated using MacVector 10.0.2. Env sequences
have been previously deposited in GenBank (accession numbers
AY35338 through AY357345, AY357465 and FJ713453) [20,22].
HIV-1 infection of PBMC
The sensitivity of the infectious viral clones to gp120-targeting
MAbs and other inhibitors was assessed as previously described
[18,20]. Briefly, 2610
5 PBMC were seeded into each well of a 96-
well culture plate after 3 days of stimulation. The PBMC consisted
of equal numbers of cells from each of the two stimulation
conditions outlined above, and were derived from two individuals.
The viral clones (at 100 TCID50) were incubated with the same
volume of culture media containing twice the desired concentration
of the inhibitor (IC9564, sCD4, BMS-806) or MAb for 1 h at 37uC.
After this incubation, 100 ml of the virus-inhibitor mixture were
added to 100 ml of PBMCs. Production of the HIV-1 p24 antigen
after 7 days of culture was quantified using an in-house ELISA [67].
Entry inhibition in the presence of MAbs or V3-targeting
compounds was calculated as 1006[12(p24MAb/p24control)], the
control being infection in the absence of an inhibitor or MAb.
Titration curves were generated using Prism (Graphpad software,
San Diego, CA) and used to determine the IC50 values.
HIV-1 infection of U87-CD4 cells expressing CCR5
mutants
U87-CD4 cells were transfected with CCR5-expressing plas-
mids using lipofectamine 2000 (Invitrogen) according to the
manufacturer’s instructions. One day after transfection, the cells
were washed twice with culture media.
One aliquot of cells was seeded into a 6-well plate and used for
determination of CCR5 expression by FACS on the following day.
Different amounts of the CCR5-WT plasmid were transfected and
the MFI value for CCR5 expression was calculated under each
condition, to generate a dose-response curve. The extent of entry
mediated by each mutant CCR5 plasmid was then compared to
that mediated by wild-type CCR5 at the same MFI value.
The remaining cells were seeded into 96-well plates at a density
of 1610
4 cells per well in 100 ml of media for one more day. Then,
freshly harvested Env-pseudoviruses were pre-incubated with
magnetic beads (ViroMag R/L; OZ Biosciences, Marseille,
France) for 15 min, added to the transfected cells at a volume of
100 ml and placed on a Super Magnetic Plate (Oz Biosciences) for
10 min, as recommended by the manufacturer. The cultures were
then maintained for 72 h at 37uC. A 100 ml aliquot of culture
supernatant was then removed and replaced with 100 ml of Bright-
Glo Luciferase Substrate (Promega Inc). After 5 min, the plates
were analyzed in a Victor3 1420 plate-reading luminometer
(Perkin Elmer, Wellesly, MA). There was no measurable
luminescence from uninfected cells.
HIV-1 infection of U87-CD4-CCR5 cells and inhibition by
rabbit sera
For studies with rabbit sera, Env-pseudoviruses were incubated
with the same volume of media containing twice the required
dilution of sera for 1 h at 37uC, then the mix was added to U87-
CD4-CCR5 cells for 72 h before measurement of luciferase
expression. The percent neutralization by rabbit sera was
calculated as previously described [68]. To correct for any
interference from rabbit serum components, a pre-immune serum
sample from the same animal was processed identically to the post-
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of the percent neutralization at each serum dilution. Percent
neutralization was defined as [12(RLUpostimmune/RLUpreim-
mune)]6100. The effect of this adjustment was, in most cases,
negligible; neutralization titers derived using the pre-immune
serum correction were usually very similar to those obtained using
the standard control wells, containing only Env-pseudoviruses and
cells, as a reference. Non-linear sigmoidal dose-response curves
were generated using Prism (Graphpad software, San Diego, CA).
gp120 capture ELISA
MAb binding to gp120 was quantified essentially as described
previously [33,69]. Supernatants from 293T cells transfected with
either PPI4-CC1/85 cl.7 or PPI4-CC101.19 cl.7, or viral lysates
served as the sources of gp120; they were added to ELISA wells
coated overnight with sheep antibody D7324 to the gp120 C-
terminus (Aalto Bioreagents, Rathfarnham, Dublin, Ireland). The
plates were washed three times with TSM (20 mM Tris, 150 mM
NaCl, 1 mM CaCl2, 2 mM MgCl2), and then blocked with TSM/
1% BSA for 30 min. MAbs diluted in TSM were then added for
2 h. The plates were washed five times with TSM/0.05% Tween,
before addition of an appropriate HRP-labeled secondary Ab in
TSM/0.05% Tween for 1 h. The colorimetric endpoint at
450 nm was determined 10 min after the addition of the substrate
solution (0.1 M sodium acetate, 0.1 M citric acid, 1% TMB
(Sigma-Aldrich, St. Louis, MO) and 0.01% H2O2). Non-linear
sigmoidal dose-response curves were generated using Prism
(Graphpad software, San Diego, CA).
Supporting Information
Figure S1 Binding of rabbit anti-V3 sera to V3 peptides.
Rabbits were immunized with V3 peptides: (A, B) Rabbits R1 and
R2 (V3-CC1/85 sequence); (C, D) rabbits R3 and R4 (V3-
CC101.19 sequence). Sera drawn on day 49 were tested for
reactivity with the CC1/85 (squares) or CC101.19 (triangles) V3
peptides in an ELISA. The OD490 values shown were corrected
for background binding, as measured using pre-immune sera. (E)
Endpoint and midpoint titers were calculated using Prism
Graphpad software.
Found at: doi:10.1371/journal.ppat.1000548.s001 (0.20 MB PDF)
Figure S2 Binding of rabbit anti-V3 sera to gp120. The titration
curves depict the binding of sera from rabbits R1 (V3-CC1/85;
closed squares), R2 (V3-CC1/85; closed circles), R3 (V3-
CC101.19; open squares) and R4 (V3-CC101.19; open circles)
to gp120 from (A) CC1/85 cl.7 or (B) CC101.9 cl.7. The OD450
values shown were corrected for background binding, as measured
using pre-immune sera.
Found at: doi:10.1371/journal.ppat.1000548.s002 (0.11 MB PDF)
Table S1 Summary of some phenotypic characteristics of CCR5
inhibitor-sensitive and -resistant viral clones.
Found at: doi:10.1371/journal.ppat.1000548.s003 (0.07 MB PDF)
Text S1 Supporting results and methods.
Found at: doi:10.1371/journal.ppat.1000548.s004 (0.09 MB PDF)
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